In response to more oral therapies, cancer centers are creating standardized oral oncolytic programs to improve patient care. Patients were prompted to input pain severity scores using a visual analog scale from 0-10 at multiple times during a day. The guidelines are based on a review of 227 articles that compared integrative therapies to a comparison group. Use of a short-course electric massage chair with standard of care helped reduce chemotherapy-induced nausea and vomiting. A recently published guideline offers suggested recommendations to support patient adherence to oral anticancer medications. Use of a 3-stage capacity-consent process provides time to show a patient’s capacity to consent to proposed cancer ... A new intervention could help restore normal functioning in the brains of chemotherapy patients through neurofeedback. A text message questionnaire identified patients with solid tumors who were not experiencing symptoms of ICI toxic effects. Various vaccines and immunotherapies such as sipuleucel-T and BCG are important to consider in preventive cancer care. A multidisciplinary treatment-related adverse events management program resulted in improvement of related toxicities. Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients. Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable splee Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure. The Australian study put men with prostate cancer receiving androgen deprivation therapy on an exercise program. Researchers evaluated whether outpatients suites could improve quality measures. The basics of PTCy after hematopoietic cell transplantation for GVHD prevention, plus, how nurses can explain PTCy to patient Cancer patients participating in medical tourism should know how seeking care outside of the US could disrupt care plan. One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer. Extending the interval of port flushes to every 12 weeks did not increase the incidence of port-related adverse events. Clinics also postponed or deferred radiation treatments and elective surgeries.